BPBT
SRPT icon

Boston Private Bank & Trust’s Sarepta Therapeutics SRPT Stock Holding History

Boston Private Bank & Trust’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-400
Closed -$19K – 1084
2013
Q3 		$19K Hold
400
– – ﹤0.01% 711
2013
Q2 		$15K Buy
+400
New +$14.3K ﹤0.01% 717

Other funds holding SRPT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Boston Private Bank & Trust's SRPT Position: Q4 2013 in Review

Boston Private Bank & Trust sold out of Sarepta Therapeutics (SRPT) in Q4 2013, closing a stake of 400 shares — an estimated $19K sold.

Boston Private Bank & Trust first reported a position in SRPT in Q2 2013 and held it in 2 quarters. The position peaked at $19K in Q3 2013. 108 funds tracked by Wall St. Rank hold SRPT as of Q4 2013.

  • Boston Private Bank & Trust reported no remaining Sarepta Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Boston Private Bank & Trust sold 400 Sarepta Therapeutics shares in Q4 2013, an estimated $19K.
  • Boston Private Bank & Trust first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 2 quarters.
  • Boston Private Bank & Trust's Sarepta Therapeutics position peaked at $19K in Q3 2013.
  • 108 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2013.

Based on Boston Private Bank & Trust's 13F filing for Q4 2013, filed 14 Jan 2014.